A San Diego biotech is developing what could be the first-ever extrachromosomal DNA-directed therapy, which aims to stop tumor growth.May 19, 2023Check out STAT+Sponsored By Courtesy Heather Landy Opinion: Starting breast cancer screening at 40 saved my life Reluctant to fit another appointment into my busy life, I almost didn't start getting mammograms in my 40s. By Heather Landy Opinion: New draft recommendations for mammograms take a one-size-fits-all approach The new recommendations are supposed to maximize lives saved while helping to address inequities in care. Will they work? By Lydia E. Pace and Nancy L. Keating STAT+ | Boundless Bio tests a cancer drug targeting once-mysterious DNA loops Boundless Bio, which last week reported it has dosed its first patient, announced on Tuesday that it raised $100 million. By Jonathan Wosen More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Cancer Briefing? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments